Quintrio
Home

BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

LeonaBio, Inc. Common Stock

LONA

LeonaBio Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for high unmet medical needs. Its key drug candidates, lasofoxifene and ATH-1105, are novel, small-molecule therapies with the potential to address treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis (ALS). LeonaBio is also exploring the use of other drug candidates that enhance the neurotrophic HGF system, including ATH-1020, to improve neuronal health and function in multiple neurological diseases. In addition, it is also focused on designing and testing new early compounds directed towards novel targets for a variety of clinical applications. The company operates as a single operating segment, developing and commercializing therapeutics.

Last trade $0.00
Day change $0.00 (0.00%)
Day range $3.03 – $3.39
Volume 13,517
Market cap $30M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$30.43M
Price / earnings
—
Price / book
0.91×
Price / sales
—
EV / sales
—
EV / EBITDA
0.02×

Profitability

Earnings per share
-$15.01
Return on assets
-248.64%
Return on equity
-421.09%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
7.01×
Quick ratio
7.01×
Cash ratio
4.13×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$61.93M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for LONA, quarterly periods
Line itemQ2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026
Revenue$0$0
Cost of revenue$0$0
Gross profit$0$0
Selling, general and administrative$6.58M$6.88M
Research and development$12.7M$11.26M
Total operating expenses$19.45M$17.21M
Operating income-$19.45M-$17.21M
Interest expense$0$0
Income before taxes-$19.01M-$32.96M
Income taxes$0$0
Net income-$19.01M-$32.96M
Net income attributable to common shareholders-$19.01M-$32.96M
EBITDA-$19.23M-$16.98M
Basic earnings per share-$0.80-$1.73
Diluted earnings per share-$0.80-$1.73

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

LeonaBio to Participate in Upcoming Medical and Industry Meetings in June

LeonaBio, a clinical-stage biopharmaceutical company, announced its participation in two major industry conferences in June 2026. The company will present on its lead ALS candidate ATH-1105 at the ALS Drug Development Summit and participate in an oncology panel at the BIO International Convention. LeonaBio also announced board appointments of three new directors.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Sep 18, 20251-for-10reverse split